Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 17/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 17/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 17/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202199 | 0.78 | KMT2A (0.40) | OPRL1OPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL2197918 | 0.77 | OPRD1 (0.44) | OPRM1OPRD1OPRK1MEN1KMT2A | |
| SCHEMBL6775745 | 0.76 | OPRL1 (0.52) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL14635953 | 0.75 | OPRM1 (0.69) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL15155645 | 0.75 | OPRD1 (0.57) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL27788821 | 0.74 | CTSK (0.45) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL4388699 | 0.73 | KMT2A (0.45) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL27979542 | 0.72 | OPRD1 (0.51) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL6498050 | 0.71 | OPRL1 (0.73) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL15156334 | 0.71 | OPRL1 (0.73) | OPRL1OPRM1OPRD1OPRK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | OPRL1 4259/4885OPRM1 4824/4885OPRD1 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.